Immune Repertoire Sequencing Market Analysis

  • Report ID: 3997
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Immune Repertoire Sequencing Market Segmentation:

Product Type Segment Analysis 

The assay kits segment in the immune repertoire sequencing market is set to witness the highest revenue share of 60% by the end of 2035. Assay kits are distributed into TCR kits and BCR kits. The TCR is a significant part of the human adaptive immune system. With the help of this system pathogenic are being identified, recalled, and destroyed. Therefore, various companies are signing agreements and merging in order to offer repertoire sequencing kits for a specific type of immunotherapy.

End User Segment Analysis 

The immune repertoire sequencing market from the pharmaceutical segment is poised to experience the largest demand throughout the projected period. Pharmaceutical companies primarily use immune repertoire sequencing to recognize and validate potential therapeutic targets. By knowing the functionality and diversity of immune cells and receptors they can make drugs that can modulate immune responses.

Moreover, pharmaceutical companies often collaborate with research organizations, academic institutions, and sequencing technology providers for advanced immune repertoire sequencing research.

Our in-depth analysis of the global market includes the following segments:

        Product Type

  • Instruments
  • Assay Kits

          Application

  • Cancer Immunotherapy
  •  Biomarker Discovery
  • Autoimmune Diseases
  • Vaccine Development and Efficacy
  • Transplant Rejection and Tolerance
  • Infectious Diseases

          End User

  • Pharmaceutical Companies
  • Research Institutes
  • Diagnostic Labs

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of immune repertoire sequencing is estimated at USD 397.74 million.

The global immune repertoire sequencing market size was around USD 366.11 million in 2025 and is likely to expand at a CAGR of more than 9.6%, surpassing USD 915.62 million revenue by 2035.

North America immune repertoire sequencing market will hold around 40.8% share by 2035, driven by high healthcare spending and strong demand for immunotherapy.

Key players in the market include Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, Atreca Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos